FDA approves Abilify MyCite, a drug that digitally tracks when it’s ingested

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has approved the first-ever pill that digitally tracks when a patient takes it.
  • The pill, aripiprazole (Abilify MyCite), has an embedded sensor (Proteus Digital Health) that sends a message to a skin patch upon ingestion; the patch relays the information to the user’s smartphone.
  • Patients can give clinicians or caregivers access to the information via a web portal.

Why this matters

  • Remembering to take medications can be difficult for any patient.
  • Patients with the conditions that this drug treats, including schizophrenia and bipolar disorder, can struggle with executive function, including remembering to take medications or when they last took them. 

Highlights

  • Prescribing information for this drug notes that effects on drug adherence have yet to be shown. 
  • The FDA allowed marketing of the sensor in 2012 but delayed approval of Abilify MyCite in 2016, calling for more information.
  • Aripiprazole comes with a boxed warning that elderly patients with dementia-related psychosis are at increased mortality risk with antipsychotic drug treatment, and the sensor-equipped version is not approved for patients with dementia-related psychosis.
  • The warning also notes increased risk for children, adolescents, and young adults for suicidal thinking and behavior.
  • Abilify MyCite safety and effectiveness are not established in the pediatric population.